Last year Clinuvel delivered pretty amazing 47% NPAT growth for...

Last year Clinuvel delivered pretty amazing 47% NPAT growth for a cool $30.6 Million profit figure, cash now is ~$200 Million, no debts, absolute monopoly status and a Phase 3 running in a blockbuster indication for an already FDA, EMA approved drug that we would probably all love to have access to. That's all good but sometimes the management just appear inept, don't get me started on the buyback which should be an amazing development for shareholders after all their fighting words - but now despite weeks and years of manipulations they refuse to even buyback shares with the exception of a couple of tiny parcels at the $15 figure. That 5 year low $15 figure took a lot of work and fake liquidity over many years for the shorters to arrive at and maintain and now Clinuvel refuse to buy shares above this artificial figure which is really generous for the shortsellers and totally against supporting shareholder interests. Look at Cochlear; words: BUYBACK $75 Million and ACTION, $75 Million bought back on market simply and without fuss and Cochlear shareholders happy. Clinuvel words: BUYBACK 1.5 Million shares, ACTION (nearly 4 months later) less than 50 thousand shares bought back. This needs to change, actions need to match words in support of shareholders.

Cochlear is a great Australian Biotech and exceptionally managed just like CSL. Some have mentioned NICE and the slow EPP rollout, here is an interesting contrast in style to getting an earlier rejection decision from NICE reversed. This is by Australia's greatest Biotech and possibly Australia's greatest company in CSL. Excellent recent article in pharmaphorum worth reading, this is from the article

"In the UK, health technology assessment agency NICE has reversed an earlier decision to reject coverage of Hemgenix (etranacogene dezaparvovec) by NHS England last year.." also by way of comparison Hemgenix "has a list price of £2.6 million ($3.3 million) in the UK ".

This all happened in about one year with the CSL rejection/reversal, by way of comparison Clinuvel was rejected by NICE back in 2017 I think and Clinuvel have won multiple appeals against NICE since then but still have not got any reversal after so many years. CSL proving much more successful for their patients in this regard, hopefully Clinuvel are eventually successful in getting their treatment funded by NICE before PW finishes up. Two very different outcomes for patients by two Australian Biotech companies. Link to article below.

Interestingly they also got approval in Denmark and the article quoted the price for the therapy as being higher in the UK than in Denmark ($3.1 million)?. And those prices are USD I believe.

https://pharmaphorum.com/news/england-denmark-back-csls-haemophilia-b-gene-therapy

ALL IMO DYOR